Repligen Stock Price, News & Analysis

Repligen Corporation (NASDAQ:RGEN) announced its participation in the KeyBanc Life Science and MedTech Investor Forum on March 22-23, 2022. CEO Tony J. Hunt will engage in a fireside chat on March 22 at 9:45 a.m. EDT. A live webcast of the event will be available on the company’s Investor Relations website and can be replayed for a limited time afterward. Repligen is a leader in bioprocessing technology, supporting biopharmaceutical developers worldwide.

908 Devices (Nasdaq: MASS) has appointed Tony J. Hunt, President and CEO of Repligen Corporation (Nasdaq: RGEN), to its Board of Directors. Mr. Hunt brings over 20 years of experience in life sciences and bioprocessing. His previous roles include Chief Operating Officer at Repligen and President of Bioproduction at Life Technologies. The appointment aims to enhance 908 Devices' strategic insights and support its goal of developing a comprehensive bioanalytics platform. The company specializes in handheld mass spectrometry devices for critical applications in various markets.

Repligen Corporation (NASDAQ:RGEN) announced record revenue of $186.5 million for Q4 2021, marking a 72% increase year-over-year. For the full year, revenue reached $670.5 million, growing 83%. The company reported organic growth of 69% in Q4 and 71% for the year. Key metrics included a GAAP operating margin of 20.1% and an adjusted EPS of $0.81. Looking forward, RGEN anticipates revenue between $800-$830 million for 2022, predicting growth of 19%-24%.

Repligen Corporation (NASDAQ:RGEN) has launched three advanced affinity chromatography resins under the AVIPure® brand, designed specifically for gene therapy manufacturing. The resins—AVIPure® - AAV9, AVIPure® - AAV8, and AVIPure® - AAV2—were developed by Avitide LLC, addressing the demand for high-performance and caustic-stable solutions in the industry. This launch aims to enhance the efficiency and economics of gene therapy workflows. The company anticipates benefiting from strong customer adoption and expanded product lines in the future.

Repligen Corporation (NASDAQ:RGEN) will present virtually at the 11th Annual SVB Leerink Healthcare Conference from Feb. 14-18, 2022. Tony J. Hunt, President and CEO, is scheduled for a fireside chat on Feb. 18 at 3:00 p.m. EST. A live webcast will be available on Repligen's Investor Relations page and will be accessible for replay shortly after the event.

The company is a leader in bioprocessing technology, enhancing efficiencies for biopharmaceutical manufacturers.

Repligen Corporation (NASDAQ:RGEN) will report its Q4 and full year 2021 financial results on February 17, 2022. A press release will be issued prior to market opening, and a conference call is scheduled for 8:30 a.m. EST to discuss the results and business updates for the periods ending December 31, 2021. The call can be accessed via toll-free numbers or through a webcast.

Repligen Corporation (NASDAQ:RGEN) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference from January 10-13, 2022. CEO Tony J. Hunt is scheduled to present on January 12 at 9:45 a.m. EST. Investors can access a live webcast of the presentation on Repligen’s Investor Relations website, with a replay available for a limited time post-event. Repligen is a leader in developing innovative bioprocessing technologies that enhance the manufacturing of biological drugs, serving biopharmaceutical developers and CDMOs globally.

Repligen Corporation (NASDAQ:RGEN) announced its participation in two investor conferences. The first is Stifel’s 2021 Virtual Healthcare Conference from November 15-17, where CEO Tony J. Hunt will hold a fireside chat on November 17 at 8:00 a.m. EST. The second is the Stephens Annual Investment Conference from December 1-3, featuring CFO Jon K. Snodgres on December 3 at 11:00 a.m. EST. Live webcasts will be accessible through the Investor Relations section of the company’s website, with replays available thereafter.